Chenodeoxycholic acid
metaboliteBile acid dysregulation associated with acute coronary syndrome, acting as a systemic metabolic marker rather than a direct atherothrombotic mechanism.
Pathway placement
Cascade stepOff-pathway / systemic markers
Confidencelow
RationaleBile acid metabolism marker; systemic metabolic axis independent of atherothrombotic cascade.
Druggability
Not assessed (no mapped human gene target).
Type I vs Type II discrimination
ScoresLow-confidence (proxy)
R — rupture / Type-I28
C — confounder / Type-II58
A — assay feasibility42
E — evidence strength22
T1DI (composite)3
Specificity differential (R−C)-29.5
Confounder panel (Type-II drivers)
No confounder evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.
Assay & specimen
Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum, plasma or urine
Collection tube
Serum separator (gold/red-top, SST) · Lithium heparin (green-top) · Sterile urine container
Method / principle
LC-MS/MS (targeted metabolomics) or enzymatic colorimetric where available
Reagent / substrate
Stable-isotope-labeled internal standard (MS); or enzyme-coupled Trinder reagent
Platform
LC-MS/MS; some automated chemistry
Turnaround · availability
Send-out / research · Specialized / research
Literature evidence(2)
- The impact of hypertension for metabolites in patients with acute coronary syndrome.Annals of translational medicine · 2023 · PMID 36819519 · doi
- The Synergistic Mechanism of Total Saponins and Flavonoids in Notoginseng-Safflower against Myocardial Infarction Using a Comprehensive Metabolomics Strategy.Molecules (Basel, Switzerland) · 2022 · PMID 36557992 · doi